Cynosure Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cynosure Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-950	Closed	-$378K	–	215
2025 Q4	$378K	Buy	+950	New	+$420K	0.04%	382

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cynosure Group's ALNY Position: Q1 2026 in Review

Cynosure Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 950 shares — an estimated $378K sold.

Cynosure Group first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $378K in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Cynosure Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Cynosure Group sold 950 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $378K.
Cynosure Group first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Cynosure Group's Alnylam Pharmaceuticals position peaked at $378K in Q4 2025.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.